The NIDA/SAMHSA-ATTC Blending Initiative: New Tools for Bringing Research into Clinical Settings Beth Rutkowski, M.P.H., & Thomas Freese, Ph.D. UCLA Integrated.

Slides:



Advertisements
Similar presentations
Evidence Based Practices Lars Olsen, Director of Treatment and Intervention Programs Maine Department of Corrections September 4, 2008.
Advertisements

The Institute for learning and Development A New York State Office of Alcoholism and Substance Abuse (OASAS) certified education and training provider.
Development of the Consumer Professional Partnership Program (CPPP) Thilo Kroll NRH CHDR Steve Towle SCI Network RRTC on SCI: Promoting Health and Preventing.
Overview of Outreach competencies Stephen J. Gumbley, MA, ACDP II Director, New England ATTC.
Ensuring Quality Services and the Protection of Patients’ Welfare A GPS for quality care. Jeanne L. Obert Executive Director Matrix Institute on Addictions.
PFR/ATTC Leadership Institute. Partners for Recovery Overview A collaboration of communities and organizations mobilized to help Individuals and families.
The Standards of Practice for a Tobacco Treatment Specialist (TTS) Gaylene Mooney, M.Ed., RRT-NPS, CTTS Program Director, Respiratory Therapy San Joaquin.
Section 17: Treatment Planning. 2 Icebreaker How do you define treatment planning?
Texas Department of State Health Services - Supporting Evidenced-based Practices for the Advancing Recovery Project.
Our Mission Community Outreach for Youth & Family Services, Inc. is dedicated to improving the quality of life for both the youth and adult population.
Translating Research to Practice in Treating Substance Use Disorders Richard Rawson, Ph. D. UCLA Drug Abuse Research Center Matrix Institute on Addictions.
Comparative Effectiveness Research in the National Drug Abuse Treatment Clinical Trials Network (CTN) CDR Steven Sparenborg, Ph.D., Udi Ghitza, Ph.D.,
ATTC Network Orientation: Recovery and Recovery-based Care.
What the Heck is the CTN Anyway? The NIDA National Drug Abuse Treatment Clinical Trials Network.
Motivational Interviewing to Improve Treatment Engagement and Outcome* The effect of one session on retention Research findings from the NIDA Clinical.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Addressing Crystal Methamphetamine Use Among Gay and Bisexual Men: A Treatment Center’s Response Joe Ruggiero, Ph.D. –Director, Outpatient Services The.
Leeds Dual Diagnosis Capability Framework
Pacific Southwest (Region 9) Model Training and Technology Transfer Activities California and Beyond Thomas E. Freese, PhD Pacific Southwest Addiction.
MIEDAR, PAMI and BEYOND Maxine Stitzer, Ph.D. Johns Hopkins SOM APHA Symposium Denver, CO November 10, 2010.
ATTC Network Overview Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment.
Participant Choice – Access to Recovery as a Voucher Service Delivery Model Presented to National Summit on Prisoner Re-Entry Sponsored by the White House.
This product was developed by Florida’s Positive Behavior Support Project through University of South Florida, Louis de la Parte Florida Mental Health.
Attractive Addiction Treatment...? Can we make addiction treatment engaging?
NIDA/SAMHSA Blending Initiative Overview. Advances in science are giving us a broad range of promising options for treating substance use disorders, BUT.
Evidence-Based Practice: Psychosocial Interventions Maxine Stitzer, Ph.D. Johns Hopkins Univ SOM NIDA Blending Conference June 3, 2008 Cincinnati, Ohio.
The CTN Research Utilization Committee: Putting Dissemination Research into Practice Jeffrey Selzer, MD Chair, CTN Research Utilization Committee Long.
Mental Health and Substance Abuse Services Joe Vesowate Assistant Commissioner.
Treatment 101 Substance Abuse Basics West Coast Consulting Wanda King
The Value of Ongoing Evaluation in Adopting Buprenorphine-Naloxone Short-term Taper Gregory S. Brigham, Ph.D. Maryhaven, Columbus, Ohio NIDA CTN Ohio Valley.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Harold I Perl, PhD Center for the Clinical Trials Network National Institute on Drug Abuse NIATx Summit and SAAS National Conference Boston, MA July 13,
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
Implementation Science and the Adoption of Practice in Addiction Treatment Harold I Perl, PhD Center for the Clinical Trials Network National Institute.
KENTUCKY YOUTH FIRST Grant Period August July
Module V: Coordinated Care BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
Implementation of Evidence-Based Models: Improving Processes Jeanne L. Obert, MFT, MSM Executive Director, Matrix Institute UCLA Integrated Substance Abuse.
Understanding TASC Marc Harrington, LPC, LCASI Case Developer Region 4 TASC Robin Cuellar, CCJP, CSAC Buncombe County.
MIA: STEP Toolkit Overview. NIDA-SAMHSA Blending Initiative 2 What is an MI Assessment?  Use of client-centered MI style  MI strategies that can be.
Applying Science to Transform Lives TREATMENT RESEARCH INSTITUTE TRI science addiction Mady Chalk, Ph.D Treatment Research Institute CADPAAC Conference.
Integrating Services Research into CTN Clinical Trials: The Devil is in the Details Harold I Perl, PhD Center for the Clinical Trials Network National.
Module V – Coordinated Care BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
Elizabeth WellsDennis Daley School of Social WorkWestern Psychiatric Institute University of WashingtonUniversity of Pittsbu rgh Supported by Grants #
Technology Transfer in the Innovation Process CSAT Workforce Development Committee October 20, 2009 Heather Gotham, Ph.D. Evaluator, Mid-America ATTC Laurie.
Michael Levy, Ph.D. VP of Clinical Services Northeast Behavioral Health.
SCREENING BRIEF INTERVENTION AND REFERRAL TO TREATMENT (SBIRT) 1.
Missouri’s State and Provider Partnership Terry Morris Missouri Division of Alcohol & Drug Abuse August 2008 Advancing Recovery in Missouri.
Assuring Safety for Clinical Techniques and Procedures MODULE 5 Facilitative Supervision for Quality Improvement Curriculum 2008.
Dave neilsen Deputy Director. Commitment, Knowledge and Services… The Department of Alcohol and Drug Programs (ADP) is committed to providing excellent.
Buprenorphine and the NIDA CTN: Research to Practice Walter Ling & Richard Rawson ISAP/UCLA XIII World Congress of Psychiatry September 14, 2005 Cairo,
BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment.
National Drug Abuse Treatment Clinical Trials Network Dissemination Library Meg Brunner, MLIS; Nancy Sutherland, MLS.
Abstinence Incentive Effects in Psychosocial Counseling Patients Testing Stimulant Positive vs Negative at Treatment Entry Maxine L. Stitzer Johns Hopkins.
California Addiction Training and Education Series Jeanne L. Obert, MFT, MSM Executive Director, Matrix Institute on Addictions Methamphetamine Behavioral.
UCLA Integrated Substance Abuse Programs Richard Rawson, Ph.D. Rachel Gonzales, Ph.D. Funded by: California Alcohol and Drug Programs CalOMS Training for.
Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Gaps in Substance Use Treatment Presented by: Rhonda G. Patrick, LCSW, MPA Amy C. Traylor, MSW, Ph.D.
Meg Brunner, MLIS; Nancy Sutherland, MLS Alcohol and Drug Abuse Institute, University of Washington (WA Node) The NATIONAL DRUG ABUSE TREATMENT CLINICAL.
CTN Update Betty Tai, Ph.D February 14, 2001 Who could want a more lovely way To spend Valentine’s Day Than talking about how we may Implement protocols.
ATTC Network Orientation August An Overview of the Network Mary Beth Johnson Aug. 26, 2008.
TRANSDISCIPLINARY FOUNDATION II: TREATMENT KNOWLEDGE Contributor: Lori Phelps Lori L. Phelps California Association for Alcohol/Drug Educators, 2015 Chapter.
October 15, 2015 Peter F. Luongo, Ph.D..  Alcohol misuse or abuse often goes undetected with a majority of clinicians citing lack of confidence in alcohol.
Harold I Perl, PhD Center for the Clinical Trials Network National Institute on Drug Abuse 8 th Conference of INEBRIA Boston, MA September 23, 2011.
 Pharmaceutical Care is a patient-centered, outcomes oriented pharmacy practice that requires the pharmacist to work in concert with the patient and.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
ACT Comprehensive Assessment
ATTC Network Orientation
Overview of the Addiction Technology Transfer Center Network
A Training For Multidisciplinary Addiction Professionals
Presentation transcript:

The NIDA/SAMHSA-ATTC Blending Initiative: New Tools for Bringing Research into Clinical Settings Beth Rutkowski, M.P.H., & Thomas Freese, Ph.D. UCLA Integrated Substance Abuse Programs/Pacific Southwest Addiction Technology Transfer Center

So who are the participants in this endeavor?

An Introduction to SAMHSA/CSAT

SAMHSA/CSAT To improve the lives of individuals and families affected by alcohol and drug abuse by ensuring access to clinically sound, cost-effective addiction treatment that reduces the health and social costs to our communities and the nation. CSAT's initiatives and programs are based on research findings and the general consensus of experts in the addiction field that, for most individuals, treatment and recovery work best in a community-based, coordinated system of comprehensive services. Because no single treatment approach is effective for all persons, CSAT supports the nation's effort to provide multiple treatment modalities, evaluate treatment effectiveness, and use evaluation results to enhance treatment and recovery approaches. CSAT’s Mission:

The ATTC Network

ATTC of New England Northeast ATTC Pacific Southwest ATTC Northwest Frontier ATTC Prairielands ATTC Mid-America ATTC Great Lakes ATTC Gulf Coast ATTC Mountain West ATTC Mid-Atlantic ATTC Southern Coast ATTC Southeast ATTC Central East ATTC Caribbean Basin, Hispanic/Latino & US Virgin Islands ATTC Central East ATTC Northwest Frontier ATTC ATTC National Office

An Introduction to NIDA

NIDA's mission is to lead the Nation in bringing the power of science to bear on drug abuse and addiction

So what is this thing called the CTN?

NIDA’s C linical T rials N etwork Established in 1999 NIDA’s largest initiative to blend research and clinical practice by bringing promising therapies to community treatment providers Network of 17 University-based Regional Research and Training Centers (RRTCs) involving 116 Community Treatment Programs (CTPs) in 24 states, Washington D.C., and Puerto Rico

CTN RRTC States with CTP CTN Nodes

Regional Research & Training Center Community Treatment Program Community Treatment Program Community Treatment Program Community Treatment Program Community Treatment Program CTN Node Community Treatment Program Community Treatment Program Community Treatment Program

Goals of the Agreement Take “what we know” from NIDA-funded research and produce products for use by addiction field: –Training materials –Pamphlets –Bibliographies/reading materials –On-line courses

Current Blending Teams Buprenorphine Awareness S.M.A.R.T. Treatment Planning Buprenorphine Detoxification Motivational Interviewing (MIA:STEP) Motivation Incentives (PAMI)

NIDA/SAMHSA-ATTC Initiative Blending Team Buprenorphine Treatment: A Training for Multidisciplinary Addiction Professionals

Buprenorphine Awareness Blending Team Members ATTC Members: Thomas Freese, Pacific Southwest ATTC, Chair Beth Finnerty, Pacific Southwest ATTC Glenda Clare, Central East ATTC Gail Dixon, Southern Coast ATTC NIDA Members: Leslie Amass, Friends Research Institute, Inc. Greg Brigham, CTN Ohio Valley Node Eric Strain, Johns Hopkins University

Goals for the Bup Awareness Blending Team Creation of a package of materials to increase the awareness of the usefulness of buprenorphine for treating opiate addiction among non-physician practitioners. To provide information designed to increase motivation for bringing buprenorphine to local communities as a treatment option To provide information relevant to non-physician providers about what to expect when someone is treated with buprenorphine.

Bup Awareness Blending Team Products Standup Training Package –5-6 hour awareness training –20-minute stand alone introduction CEATTC On-line Course –Self-paced option Additional Materials –Brochures –National Office Annotated Bibliography

Blending Team Products Standup Training Package – 6 modules –Module I: Introduction Myths about opiate addiction and treatment Changes in laws regarding opiate treatments Role of buprenorphine in treatment system Brief history of opiate treatment

Blending Team Products Standup Training Package – 6 modules –Module I: Introduction to Opioid Treatment What leads to opiate addiction History of opiate treatment Receptor pharmacology Use of agonists, partial agonists, and antagonists in treatment

Blending Team Products Standup Training Package – 6 modules –Module II/III: Buprenorphine/Opiate 101 Overview of the medication and how it works The role of buprenorphine in treatment –Induction –Maintenance –Medically-Assisted Withdrawal

Blending Team Products Standup Training Package – 6 modules –Module IV: Identification of Patients for Buprenorphine Treatment Where are opiate dependent patients seen? Screening and identification of opiate dependent individuals Ways for providers to facilitate treatment Understanding who is an optimal candidate for buprenorphine treatment

Blending Team Products Standup Training Package – 6 modules –Module V: Coordinated Care How to find a physician who can prescribe Bup Roles of providers Working within the scope of practices/using linkages to other providers No wrong door to treatment

Blending Team Products Standup Training Package – 6 modules –Module VI: Counseling Buprenorphine Patients Craving and Triggers Working with Special Populations Buprenorphine-Related Patient Management Issues

Key Components of this Package Available through the 14 regional ATTCs and 17 Nodes of the CTN. Designed to be completely customizable to meet the needs of each state. An important new resource for your states to assist in integrating this important new treatment in local treatment environments.

NIDA/SAMHSA-ATTC Initiative Blending Team S.M.A.R.T. Treatment Planning: Utilizing the Addiction Severity Index

S.M.A.R.T. Treatment Planning Blending Team Members ATTC Members: Richard Spence, Gulf Coast ATTC, Chair Nancy Roget, Mountain West ATTC Pat Stilen, Mid-America ATTC NIDA Members: Deni Carise, Treatment Research Institute Meghan Love, Treatment Research Institute A. Thomas McLellan, Treatment Research Institute

S.M.A.R.T Treatment Planning Utilizing the Addiction Severity Index S pecific M easurable A ttainable R ealistic T ime related

S.M.A.R.T. Treatment Planning Goal and Focus: –Transform required paperwork (e.g., ASI, psychosocial assessment) into clinically useful information –The focus of the training is on incorporating the assessment information in treatment planning and using the treatment plan to guide service delivery

S.M.A.R.T. Treatment Planning Information covered: –Addiction Severity Index (ASI) application in treatment planning –Individualized treatment plans vs. program- driven plans –Evaluation uses for program directors and clinical supervisors –Role of treatment plan in clinical records –Experiential writing exercises

Training manual including trainer notes and PowerPoint slides On-line training program Additional products –Quick guide –Lesson plans –Bibliography S.M.A.R.T Treatment Planning Utilizing the Addiction Severity Index

Module 1: Learn how the results from administering the ASI can make a counselor’s task easier and be able to discern differences between program-driven and individualized treatment plans Module 2: Identify and understand individualized treatment plans and how these plans can improve client retention/treatment outcomes Module 3: Practice formulating treatment plans using ASI information Module 4: Practice formulating documentation notes based on treatment plan progress. S.M.A.R.T Treatment Planning Course Content

NIDA/SAMHSA-ATTC Initiative Blending Team: Buprenorphine for Opioid Detoxification Based on Results from CTN Protocols for Inpatient Detox (CTN0001) and Outpatient Detox (CTN0002)

Buprenorphine Detox Blending Team Members ATTC Members: Thomas Freese, Pacific Southwest ATTC, Chair Beth Finnerty, Pacific Southwest ATTC Kay Gresham Morrison, Southeast ATTC Steven Gumbley, ATTC of New England NIDA Members: Greg Brigham, CTN Ohio Valley Node Judy Harrer, CTN Ohio Valley Node Dennis McCarty, CTN Oregon Node

Buprenorphine for Opioid Detoxification Goals: Training for physicians to conduct the 13- day buprenorphine taper evaluated through the CTN studies. Information for other multidisciplinary treatment personnel to support patients who are receiving this treatment

Buprenorphine Detox Blending Team Products Four hour classroom training program providing instruction on using buprenorphine for opioid dependent patients. Including: –Rational for providing detoxification to opioid dependent patients –Characterization of opiate withdrawal –Goals of detoxification –Results of the CTN studies –Implementation training –Patient and treatment staff perspectives –Overdose risk following detoxification

Present and Opioid Negative 0001 (Inpatient)

Present and Opioid Negative 0002 (Outpatient)

NNT: Number Needed to Treat NNT= Number of patients needed to treat to achieve 1 treatment success CTN 0001 (Inpatient) NNT for Bup/Nx 77/59 = 1.31 NNT for Clonidine 36/8 = 4.5 NNT Clonidine : BupNx = 3.44 CTN 0002 (Outpatient) NNT for Bup/Nx: 157/46 = 3.4 NNT for Clonidine: 74/4 = 18.5 NNT Clonidine : Bup/Nx = 5.44

Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA:STEP) NIDA/SAMHSA-ATTC Initiative Blending Team

Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA:STEP) Blending Team Members ATTC Members: Steven Gallon, Northwest Frontier ATTC, Chair Sherry Ceperich, Mid-Atlantic ATTC Maria del Mar Garcia, Caribbean Basin & Hispanic ATTC Denise Pyle, Mid-Atlantic ATTC Edna Quinones, Caribbean Basin & Hispanic ATTC NIDA Members: Samuel Ball, CTN New England Node John Hamilton, CTN New England Node Steve Martino, CTN New England Node

What is an MI Assessment? Use of client-centered MI style MI strategies that can be integrated into the agency’s existing intake assessment process Methods that can be used with diverse substance use problems Skills for assisting clients in assessing their own substance use Understanding the client’s perception and willingness to enter into a treatment process

Implementing MI may require: Focused clinical supervision Audio taped MI Assessment sessions Tape coding Feedback, coaching and instruction for improving skills

Benefits of MI Assessment It has a solid evidence-base MI improves client engagement and retention Using MIA:STEP:  Enhances clinical supervision  Builds counselor knowledge and proficiency in MI

Why another application of MI? Positive outcomes depend on clients staying in treatment for adequate length of time Adding MI at beginning of treatment increases client retention The type of clinical supervision needed to maintain and improve MI skills is generally lacking

The costs of implementing MI Assessment Time to learn and implement the protocol Regular review and feedback on MI skills Ongoing clinical supervision, including: - Training- Mentoring - Practice- Review of recorded interviews - Feedback- Development of learning plans The cost of recorders and supplies

Why consider this approach when staff are already trained in MI? Most trained clinicians do not use MI appropriately, effectively or consistently MI is more difficult than clinicians expect The key to successful implementation of MI is supervisory feedback and coaching

Development of the protocol The NIDA Drug Abuse Treatment Clinical Trials Network designed the protocol Designed as something that all outpatient community treatment providers could use Researchers worked directly with MI experts and treatment providers on both development and implementation.

MI Assessment “Sandwich” MI strategies during 1 st 20 min MI strategies during last 20 min MI strategies during last 20 min Agency Intake or Assessment

MIA:STEP Toolkit includes everything you need to: Introduce the idea of doing an MI assessment Train counselors and supervisors Provide ongoing supervision of MI Train supervisors to use a simple tape rating system Use an MI style of supervision

MIA:STEP Toolkit Overview 1.Briefing materials 2.Summary of the MI Assessment intervention 3.Results of the NIDA CTN Research 4.Teaching tools for enhancing and assessing MI skills 5.Tape rating guide and demonstration materials 6.Supervisor training curriculum

Promoting Awareness of Motivational Incentives (PAMI) NIDA/SAMHSA-ATTC Initiative Blending Team

Promoting Awareness of Motivational Incentives (PAMI) Blending Team Members ATTC Members: Lonnetta Albright, Great Lakes ATTC, Chair Joe Rosenfeld, Great Lakes ATTC Amy Shanahan, Northeast ATTC Anne Helene Skinstad, Prairielands ATTC NIDA Members: John Hamilton, CTN New England Node Scott Kellogg, CTN New York Node Therese Killeen, CTN South Carolina Node

Rationale for Developing the PAMI Blending Package Research has shown that motivational incentive programs using low-cost reinforcement (prizes, vouchers, clinic privileges, etc.), delivered in conjunction with onsite urine screening promotes higher rates of treatment retention and abstinence from drug abuse. This Blending Team is focusing its efforts on informing the field about successful approaches in the use of motivational incentives (also referred to as contingency management).

Motivational Incentives for Enhanced Drug Abuse Recovery Study Week Percentage Retained Improved Retention in Counseling Treatment 50% vs. 35% retained in the 12-week study using low-cost incentives.

Motivational Incentives for Enhanced Drug Abuse Recovery Week Percentage of negative samples Incentives Improve Outcomes in Methamphetamine Users 46% vs. 30% presented negative results when tested for Methamphetamines.

Motivational Incentives for Enhanced Drug Abuse Recovery Study Visit Percentage of stimulant negative samples Incentives Reduce Stimulant use in Methadone Maintenance Treatment 61% vs. 31% presented negative results when tested for stimulants.

Goals of the PAMI Blending Package Designed to acquaint the addiction treatment field with Motivational Incentives as a science- based therapeutic strategy. Elements incorporate examples of successful MI principles and strategies including the Fishbowl method. Illustrates positive outcomes and lessons learned from the NIDA Motivational Incentives Enhanced Drug Abuse Recovery (MEIDAR) CTN study.

PAMI Blending Team Products Blending Team products are currently being developed and will include a: Awareness video PowerPoint presentation Brochure Resource CD Tool Kit (supporting materials)

For more information Contact your Regional ATTC ATTC of New England Northeast ATTC Pacific Southwest ATTC Northwest Frontier ATTC Prairielands ATTC Mid-America ATTC Great Lakes ATTC Gulf Coast ATTC Mountain West ATTC Mid-Atlantic ATTC Southern Coast ATTC Southeast ATTC Central East ATTC Caribbean Basin, Hispanic/Latino & US Virgin Islands ATTC Central East ATTC Northwest Frontier ATTC ATTC National Office

More Information and Regional ATTC Web Pages Can Be Found at: ATTC National Office

The End For more information, please contact: Beth Rutkowski, M.P.H., (310) Thomas Freese, Ph.D., (310)